Sarepta Stock Takes a Hit in 2025: What’s Behind the Sharp Drop and What Investors Should Know
Sarepta Stock Plummets in Pre-Market Trading In a shocking turn of events, Sarepta stock nosedived by over 25% in pre-market trading on July 18, 2025, sending tremors through the biotech investment community. The stock, which had closed the previous day at $21.97, was trading at $16.32 , down by $5.65 , as of 9:01 AM UTC-4. The sudden drop has raised questions among analysts and retail investors alike. The biotechnology company, known for its work in genetic medicine, now finds itself at the center of investor anxiety. Who Is Sarepta Therapeutics? Founded in 1980 and headquartered in Cambridge, Massachusetts, Sarepta Therapeutics Inc. has been a prominent player in RNA-targeted therapies . Formerly known as AntiVirals Inc. and later AVI BioPharma, the company has focused extensively on rare neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD) . With a market cap...